Therapy Detail

Therapy Name Necitumumab
Therapy Description

Portrazza (necitumumab) is a fully human IgG1 mAb targeting EGFR, leading to the inhibition of downstream targets in the EGFR pathway, and thereby inhibiting cellular proliferation and invasion (PMID: 21154125). Portrazza (necitumumab) is approved for patients with metastatic squamous non-small cell lung cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Necitumumab Portrazza IMC-11F8 EGFR Antibody 27 Portrazza (necitumumab) is a fully human IgG1 mAb targeting EGFR, leading to the inhibition of downstream targets in the EGFR pathway, and thereby inhibiting cellular proliferation and invasion (PMID: 21154125). Portrazza (necitumumab) is approved for patients with metastatic squamous non-small cell lung cancer (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable Necitumumab Phase I Actionable In a Phase I clinical trial, Portrazza (necitumumab) was well-tolerated and demonstrated preliminary efficacy in patients with advanced solid tumors (PMID: 20197484). 20197484
Clinical Trial Phase Therapies Title Recruitment Status
NCT02496663 Phase I Necitumumab Osimertinib EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients With EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor Recruiting
NCT02443337 Phase II Necitumumab LY3023414 A Study of LY3023414 and Necitumumab in Squamous Lung Cancer Terminated
NCT01624467 Phase II Necitumumab A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors Completed
NCT01769391 Phase II Necitumumab Paclitaxel + Carboplatin A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer Completed
NCT02451930 Phase I Necitumumab Pembrolizumab A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC Active, not recruiting
NCT03387111 Phase Ib/II Capecitabine nab-paclitaxel Leucovorin GI-6301 GI-6207 Avelumab ETBX-021 ETBX-051 ETBX-061 Aldoxorubicin Cisplatin Cyclophosphamide Bevacizumab Necitumumab GI-4000 Cetuximab ALT-803 Fluorouracil ETBX-011 Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy Recruiting